MedTrace Logo

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

NCT06140329 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2025-03-14

No results posted yet for this study

Summary

The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.

Conditions

Sponsors & Collaborators

  • PYC Therapeutics

    lead INDUSTRY

Principal Investigators

  • Sreenivasu Mudumba, PhD · PYC Therapeutics

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-28
Primary Completion
2025-03-01
Completion
2025-03-10

Countries

  • United States
  • Australia
  • Austria
  • France
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06140329 on ClinicalTrials.gov